newsfilter
← Latest News
PR Newswire·

Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)

CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumorsClinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid